Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

South Africa variant

- PMLiVE

Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma

More than 50,000 cases of the blood cancer are diagnosed each year in Europe

- PMLiVE

Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults

RSV is associated with 15,000 hospital admissions in infants under six months every year in England

- PMLiVE

Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO

Nuvaxovid XBB.1.5 is now approved for emergency use in all 194 WHO member states

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

Researchers improve understanding of COVID-19 virus and future variants

The study aims to contribute to the design of future COVID-19 vaccines and drugs

- PMLiVE

BioNTech acquires right to Biotheus’ bispecific antibody candidate in deal worth over $1bn

PM8002 is currently being evaluated in phase 2 studies in patients with advanced solid tumours

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

International study reveals how to measure long COVID severity and impact

A set of 12 recommendations were established for scientific and clinical communities

- PMLiVE

Pfizer’s Litfulo approved by MHRA for adults and adolescents with alopecia areata

The autoimmune disease affects approximately 147 million people globally

- PMLiVE

Novavax’s XBB.1.5-adapted COVID-19 vaccine receives EC approval

Individuals aged 12 years and older will be eligible to receive the updated COVID-19 vaccine

- PMLiVE

The Power of Disease Awareness in Infectious Disease Education at IDWeek 2023

Medscape Education had one of its biggest conferences of the year with IDWeek 2023, hosting six educational symposia and presenting five scientific posters highlighting the outcomes of recent infectious disease...

Medscape Education Global

- PMLiVE

Pfizer and BioNTech’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links